Solvay, Innogenetics renew biomarker collaboration for three more years

By Lisa Kerner

Erie, Pa., May 3 - Solvay Pharmaceuticals and Innogenetics renewed their research collaboration for three more years.

The two companies have collaborated on a program to explore new targets for Solvay's drug development activities since 1997.

The program extension allows Solvay and Innogenetics to complete ongoing target validation and to develop biomarkers for selected Solvay therapeutics programs.

Under the agreement renewal, Innogenetics retains rights for development of biomarkers for commercialization as diagnostic kits.

"The number of identified targets has exceeded our expectations," Solvay's head of global drug discovery, Les Turski, commented about the collaboration in a news release.

"The collaboration with Innogenetics has proven to be of strategic importance for Solvay's target discovery programs in support of its long-term pharmaceutical research activities, and holds potential to support therapeutic decision making using targeted companion diagnostics."

With a U.S. office in Marietta, Ga., Solvay is focused on the therapeutic areas of neuroscience, cardio-metabolic, influenza vaccines, pancreatic enzymes, gastroenterology, and men's and women's health.

Innogenetics is a Gent, Belgium, biopharmaceutical company specializing in diagnostics and therapeutic vaccines.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.